Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Sponsor: St. Petersburg State Pavlov Medical University
Summary
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
Key Details
Gender
All
Age Range
Any - 18 Years
Study Type
INTERVENTIONAL
Enrollment
22
Start Date
2024-09-01
Completion Date
2031-09-01
Last Updated
2025-03-11
Healthy Volunteers
No
Interventions
Nivolumab
Nivolumab 40 mg on Day 2 is added to dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R).Standard guidelines for conducting the DA-EPOCH-R protocol will be used.
Locations (2)
Dmitry Rogachev National Research Center
Moscow, Russia
Pavlov University, RM Gorbacheva Research Institute
Saint Petersburg, Russia